Product Description
Tinlarebant as an oral daily treatment to target RBP4 (retinol binding protein 4), disrupting vitamin A (retinol) binding to RBP4 (Sourced from: )
Mechanisms of Action: RBP4 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Stargardt Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: RBP4
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, China, Czech Republic, France, Germany, Hong Kong, Japan, Netherlands, Switzerland, Taiwan, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Geographic Atrophy|Macular Degeneration|Stargardt Disease
Phase 1: Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PHOENIX | P3 |
Recruiting |
Geographic Atrophy |
2027-08-31 |
42% |
| DRAGON II | P3 |
Recruiting |
Macular Degeneration|Stargardt Disease |
2027-06-01 |
|
| LBS-008-CT05 | P3 |
Unknown Status |
Geographic Atrophy |
2025-11-25 |
|
| LBS-008-CT03 | P3 |
Unknown Status |
Stargardt Disease |
2025-09-19 |